Kailera Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 12.67 USD (Oct 30, 2026, 2:47 PM EDT) · Market cap 1.64B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights...